“Where Do Things Stand?” and Other Common Pleas from Clinical Trial Sponsors”
Ellie Brightman May 1, 2026
“Where do things stand?” sounds like a simple question, but fragmented trial information can make the answer surprisingly difficult. This article looks at why portfolio visibility becomes harder as studies, systems, and reporting layers multiply.
